Last reviewed · How we verify
NCT07191210: CTP
Co-Designed Comprehensive Transition Programme for First-Line Nurse Managers
NA trial testing Comprehensive Transition Programme (CTP) in Transition to First-Line Nurse Manager Role in 22 participants. Not yet recruiting.
19 December 2025
Quick facts
| Lead sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 22 |
| Start date | 3 October 2025 |
| Primary completion | 19 December 2025 |
| Estimated completion | 19 December 2025 |
Drugs / interventions tested
- Comprehensive Transition Programme (CTP)
Conditions studied
- Transition to First-Line Nurse Manager Role — all drugs for Transition to First-Line Nurse Manager Role →
Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Who can join
Eligibility, any sex, with Transition to First-Line Nurse Manager Role. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will pilot a Comprehensive Transition Programme (CTP) to support nurses who move into first-line nurse manager (FLNM) roles at Clínica Universidad de Navarra. The transition to frontline management can be challenging and is linked to uncertainty, workload stress, and role ambiguity. The CTP was co-designed with clinical nurses, FLNMs, nursing directors and chief nursing officers using experience-based co-design methods so that its content fits the organisation's practice model and priorities. The programme combines classroom training, online learning, mentorship, and structured reflective practice. Participants complete brief assessments before and after the programme. The primary focus is to see whether leadership practices improve; we will also examine feasibility and acceptability to inform future refinement. This pilot uses a simple pre-post design with data collected at baseline and immediately after the programme. Findings will be used to optimise the CTP and to guide broader implementation in the health system. (Eligibility, outcomes, dates and intervention components are detailed in their specific sections of this record.)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07191210
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Clinica Universidad de Navarra, Universidad de Navarra trials
Trials by the same sponsor.
- NCT07370571 — NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE) · not yet recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
- NCT07447440 — Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases · recruiting
- NCT07132060 — MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer · NA · not yet recruiting
- NCT07184216 — Effect of a Person-Centred Care Intervention for Families Providing Home-Based Care to a Person With Advanced Chronic Il · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07191210 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinica Universidad de Navarra, Universidad de Navarra
- Last refreshed: 24 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07191210.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing